Morgan Stanley Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price objective boosted by Morgan Stanley from $314.00 to $319.00 in a report released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of several other reports. Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $337.00 target price for the company. Royal Bank Of Canada increased their target price on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a research report on Tuesday. Canaccord Genuity Group set a $300.00 price target on Jazz Pharmaceuticals in a report on Wednesday, August 26th. Finally, Needham & Company LLC lifted their price target on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $293.45.

Read Our Latest Stock Analysis on JAZZ

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $229.74 on Tuesday. Jazz Pharmaceuticals has a 12-month low of $128.80 and a 12-month high of $266.38. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average price of $230.67 and a 200-day moving average price of $216.80. The firm has a market capitalization of $14.91 billion, a PE ratio of 78.14, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.04) by $0.16. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.55% and a net margin of 4.37%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm posted $8.13 earnings per share. As a group, equities research analysts forecast that Jazz Pharmaceuticals will post 10.87 EPS for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the sale, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $250.13, for a total value of $1,500,780.00. Following the transaction, the director owned 351,875 shares in the company, valued at approximately $88,014,493.75. This trade represents a 1.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 94,121 shares of company stock worth $23,337,922. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in JAZZ. Bank of New York Mellon Corp increased its holdings in shares of Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after acquiring an additional 517,514 shares in the last quarter. Tri Locum Partners LP purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at $29,995,000. Bank of America Corp DE grew its holdings in shares of Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after buying an additional 99,656 shares during the last quarter. Amundi increased its position in shares of Jazz Pharmaceuticals by 2,445.3% in the 1st quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock valued at $10,519,000 after acquiring an additional 53,454 shares during the period. Finally, Rokos Capital Management LLP acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $9,833,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

  • Positive Sentiment: Better-than-expected results and higher guidance: Third-quarter revenue was $1.24 billion, up 10.4% year over year and above the $1.21 billion consensus. The reported $3.88-per-share loss was narrower than analysts expected. Jazz raised its 2026 revenue forecast to about $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Jazz Pharmaceuticals third-quarter results
  • Positive Sentiment: $500 million share buyback: The repurchase authorization may support shareholder returns and signals management’s willingness to return capital. Jazz Pharmaceuticals announces share buyback
  • Positive Sentiment: Analyst target increases: JPMorgan, Morgan Stanley, RBC and Barclays raised their price targets and maintained positive ratings, adding to the favorable reaction to results and guidance. JPMorgan analyst recommendations Morgan Stanley analyst recommendations
  • Neutral Sentiment: Pipeline updates ahead: Jazz plans to present neuro-oncology research, including progress in its Phase 3 ACTION trial, at a November meeting. Any investment impact may depend on the data and subsequent development progress. Jazz neuro-oncology research at SNO 2026
  • Negative Sentiment: Loss versus prior-year earnings: The quarterly per-share loss contrasts with earnings of $8.13 a year earlier, and coverage noted an Actio-related charge. This tempers the otherwise strong revenue and outlook news. Jazz reports quarterly loss and beats revenue estimates

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

Featured Articles

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.